Trouble viewing this email? Click here to view as a webpage.
Dear dog lover:
We hope you enjoy the second issue of e-Barks, the e-mail newsletter of the AKC Canine Health Foundation. We look forward to sharing the latest in canine health research with you. Please contact us and tell us what you would like to see in future issues.
Health Tracks: Transitional Cell Carcinoma In many respects, Frankie was a lucky dog. Just a few years ago Frankie’s diagnosis of transitional cell carcinoma (TCC) would have been a death sentence. Dogs with this most common type of urinary bladder cancer had a zero chance of survival because there was no known treatment for the disease. Fortunately for Frankie and other dogs, times are changing. Thanks to ongoing research supported by grants from the AKC Canine Health Foundation, the past decade has seen great progress in managing TCC. Read more about Frankie and TCC research.
Featured Grant: A Computer Model for Cranial Cruciate Ligament Deficiency Cranial cruciate ligament (CrCL) deficiency is one of the most common orthopedic problems in dogs, having an economic impact of more than $1 billion in the US in 2003. Despite such prevalence, CrCL deficiency is still poorly understood. Dr. Gina Bertocci is developing a pelvic limb simulation model of canine walking to gain an improved understanding of knee biomechanics and factors that predispose dogs to CrCL rupture. Read more about this grant and how the model will be used.
Health Tips: Vaccines & Vaccination Protocols Vaccinations can be a controversial subject. Which vaccines, how often and at what age are all questions that are raised by dog owners. While each of us has to decide what is right for our individual dog, there are some basics that can guide you through the process. Read more about core and non-core vaccines.
Scottish Terrier and Rottweiler photos copyright of Miguel Betancourt.
To ensure that you receive our emails, please add email@example.com to your address book. Update your email preferences. Forwardthis email to your friends. If you were forwarded this email, please subscribe now.